2023 World Conference on Lung Cancer (Posters)-EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases

EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases - PDF(Slides)

Back to course

Pdf Summary

The study analyzed the prognosis of using immunotherapy in combination with whole brain radiotherapy (WBRT) for patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). The researchers retrospectively analyzed patients with driver-gene-negative NSCLC-BMs and stable extracranial control, comparing the outcomes of immunotherapy plus WBRT with chemotherapy versus WBRT alone with chemotherapy. They assessed treatment efficacy using RANO-BM criteria and evaluated primary endpoints of intracranial progression-free survival (iPFS) and intracranial response, as well as secondary endpoints of progression-free survival (PFS) and overall survival (OS). <br /><br />The results showed that patients treated with immunotherapy plus WBRT had better survival outcomes compared to those treated with WBRT alone. In the immunotherapy plus WBRT group, patients treated with concurrent therapy or immunotherapy after WBRT had better outcomes than those treated with immunotherapy before WBRT. The addition of immunotherapy to WBRT also increased the intracranial overall response rate. <br /><br />The study enrolled a total of 257 patients, 117 of whom received immunotherapy plus WBRT, and 140 received WBRT alone. The researchers concluded that the addition of immunotherapy to WBRT may improve survival outcomes in NSCLC patients with BMs. They also found that starting immunotherapy as soon as possible, no later than 2 weeks after WBRT, resulted in significantly enhanced intracranial control. On the other hand, a longer interval of more than 2 months between immunotherapy and WBRT was associated with decreased intracranial control and survival. <br /><br />In conclusion, the study suggests that combining immunotherapy with WBRT may be a beneficial treatment approach for NSCLC patients with BMs, and the timing of when to start immunotherapy in relation to WBRT is important for achieving optimal outcomes.

Asset Subtitle

Shilan Luo

Meta Tag

Speaker Shilan Luo

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immunotherapy

whole brain radiotherapy

NSCLC

brain metastases

chemotherapy

progression-free survival

overall survival

concurrent therapy

intracranial control

timing